Literature DB >> 31760507

Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease.

André Jakob1, Eva Schachinger2, Simon Klau3, Anja Lehner4, Sarah Ulrich4, Brigitte Stiller2, Barbara Zieger5.   

Abstract

Elevated von Willebrand factor (vWF):Antigen plasma levels have been observed in conjunction with cardiovascular diseases or vasculitis. The association of Kawasaki disease, a vascular inflammatory disease and vWF:Antigen, vWF:Collagen binding activity, and vWF multimers is unknown. We therefore investigated vWF parameters in 28 patients with acute Kawasaki disease in association with disease activity and coronary artery lesions. VWF:Antigen and vWF:Collagen binding activity were assessed via enzyme-linked immunoassay. The ratio of both (vWF:Collagen binding activity and VWF:Antigen) was calculated and vWF multimeric structure analysis performed. We analyzed the association between vWF parameters and our clinical data focusing on coronary artery outcome. VWF:Antigen and vWF:Collagen binding activity levels were significantly higher in the acute than in the disease's convalescence phase, and correlated positively with CRP levels. Neither variable was associated with coronary artery lesions. The vWF:Collagen binding activity/vWF:Antigen ratio, however, was significantly decreased in patients with a coronary artery lesion (z-score > 2; N = 10; mean ratio 0.96 vs. 0.64; p = 0.031) and even more so in those with a coronary artery aneurysm (z-score > 2.5; N = 8; mean ratio 0.94 vs. 0.55; p = 0.02). In a sub-analysis, those patients with a very low ratio in the acute phase presented a persistent coronary artery aneurysm at their 1-year follow-up.
Conclusion: This study suggests that comprehensive analysis of vWF parameters may help to both monitor KD inflammation and facilitate the identification of those patients carrying an increased risk for coronary artery lesion.What is Known:• Von Willebrand factor (VWF)-parameters represent surrogate markers for vascular inflammation.• Kawasaki disease is a generalized vasculitis in children, which can be complicated by coronary artery lesions.What is New:• In those Kawasaki disease patients with coronary artery lesions, the vWF:CB/vWF:Ag ratio was significantly decreased.• VWF parameters may help to identify patients at risk for coronary artery lesions.

Entities:  

Keywords:  Coronary artery lesion; Inflammation; Kawasaki disease; von Willebrand factor

Mesh:

Substances:

Year:  2019        PMID: 31760507     DOI: 10.1007/s00431-019-03513-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress.

Authors:  A Bernardo; C Ball; L Nolasco; H Choi; J L Moake; J F Dong
Journal:  J Thromb Haemost       Date:  2005-03       Impact factor: 5.824

2.  von Willebrand factor is an acute phase reactant in man.

Authors:  B E Pottinger; R C Read; E M Paleolog; P G Higgins; J D Pearson
Journal:  Thromb Res       Date:  1989-02-15       Impact factor: 3.944

Review 3.  von Willebrand factor: the old, the new and the unknown.

Authors:  P J Lenting; C Casari; O D Christophe; C V Denis
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

4.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition).

Authors:  Mamoru Ayusawa; Tomoyoshi Sonobe; Shigeru Uemura; Shunnichi Ogawa; Yoshikazu Nakamura; Nobuyuki Kiyosawa; Masahiro Ishii; Kensuke Harada
Journal:  Pediatr Int       Date:  2005-04       Impact factor: 1.524

Review 5.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

6.  Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease.

Authors:  M C Nash; V Shah; M J Dillon
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  Blocking von Willebrand factor for treatment of cutaneous inflammation.

Authors:  Carina Hillgruber; Annika K Steingräber; Birgit Pöppelmann; Cécile V Denis; Jerry Ware; Dietmar Vestweber; Bernhard Nieswandt; Stefan W Schneider; Tobias Goerge
Journal:  J Invest Dermatol       Date:  2013-06-28       Impact factor: 8.551

8.  Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.

Authors:  Aubrey Bernardo; Chalmette Ball; Leticia Nolasco; Joel F Moake; Jing-fei Dong
Journal:  Blood       Date:  2004-03-16       Impact factor: 22.113

Review 9.  Corticosteroids for the treatment of Kawasaki disease in children.

Authors:  Andrew J Wardle; Georgia M Connolly; Matthew J Seager; Robert Mr Tulloh
Journal:  Cochrane Database Syst Rev       Date:  2017-01-27

Review 10.  Dissecting Kawasaki disease: a state-of-the-art review.

Authors:  S M Dietz; D van Stijn; D Burgner; M Levin; I M Kuipers; B A Hutten; T W Kuijpers
Journal:  Eur J Pediatr       Date:  2017-06-27       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.